Hidradenitis suppurativa responding to treatment with infliximab

被引:24
|
作者
Lasocki, Anita [1 ]
Sinclair, Rodney [2 ,3 ]
Foley, Peter [2 ,3 ,4 ]
Saunders, Helen [2 ,4 ]
机构
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] St Vincents Hosp Melbourne, Fitzroy, Vic 3065, Australia
[3] Univ Melbourne, Dept Med Dermatol, Fitzroy, Vic 3065, Australia
[4] Skin & Canc Fdn, Fitzroy, Vic, Australia
关键词
anti-tumour necrosis factor monoclonal antibody; biologic; EFFICACY;
D O I
10.1111/j.1440-0960.2010.00623.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
A series of four cases of severe recalcitrant hidradenitis suppurativa treated with infliximab is presented. All patients had failed to respond to prior medical and surgical management. Baseline Quantiferon-TB Gold and chest radiograph were carried out before commencement of treatment. No patients had associated Crohn's disease. All patients received induction infusions of infliximab 5 mg/kg at weeks 0, 2 and 6, followed by eight weekly maintenance infusions. The total number of infusions varied between 4 and 6. Skin photography with Sartorius scoring was used to evaluate response to treatment. All patients experienced marked improvement in their disease activity, with a mean 48% improvement in Sartorius score after one infusion (week 2, P < 0.01), and 70% improvement after three infusions (week 14, P < 0.01). Time to relapse following cessation of therapy ranged from 6 weeks to 4 months. Further studies examining the efficacy of infliximab and its effect on the course of the disease, particularly relating to long-term management, are required.
引用
收藏
页码:186 / 190
页数:5
相关论文
共 50 条
  • [1] Treatment of Hidradenitis Suppurativa with Infliximab
    Torres, Tiago
    Selores, Manuela
    [J]. ANAIS BRASILEIROS DE DERMATOLOGIA, 2010, 85 (04) : 576 - 576
  • [2] Infliximab for the treatment of hidradenitis suppurativa
    Lebwohl, B
    Sapadin, AN
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (05) : S275 - S276
  • [3] Infliximab for the treatment of hidradenitis suppurativa
    Fernandez-Vozmediano, J. M.
    Armario-Hita, J. C.
    [J]. DERMATOLOGY, 2007, 215 (01) : 41 - 44
  • [4] Infliximab treatment for hidradenitis suppurativa
    Pilar Arevalo, Maria
    Fonseca, Eduardo
    Magdalena Verea, Maria
    Victoria Nespereira, Maria
    Rodriguez, Romina
    Fernandez-Torres, Rosa
    Paradela, Sabela
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB16 - AB16
  • [5] Hidradenitis suppurativa in Crohn's disease responding to infliximab
    Stipho, S
    Welch, R
    Feller, E
    Shah, SA
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S163 - S163
  • [6] Hidradenitis suppurativa: Response to treatment with infliximab
    Lee, CT
    Dempsey, J
    Miller, J
    King, L
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P43 - P43
  • [7] Infliximab for hidradenitis suppurativa
    Sullivan, TP
    Welsh, E
    Kerdel, FA
    Burdick, AE
    Kirsner, RS
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (05) : 1046 - 1049
  • [8] HIDRADENITIS SUPPURATIVA. RESPONSE TO TREATMENT WITH INFLIXIMAB
    Pedraz, J.
    Dauden, E.
    Perez-Gala, S.
    Goiriz-Valdes, R.
    Fernandez-Penas, P.
    Garcia-Diez, A.
    [J]. ACTAS DERMO-SIFILIOGRAFICAS, 2007, 98 (05): : 325 - 331
  • [9] Severe hidradenitis suppurativa responding to treatment with secukinumab
    Thorlacius, L.
    Riis, P. Theut
    Jemec, G. B. E.
    [J]. EXPERIMENTAL DERMATOLOGY, 2017, 26 : 3 - 3
  • [10] Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa
    Oskardmay, Ashley N.
    Miles, J. Alex
    Sayed, Christopher J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB45 - AB45